ArticleAnatomy & cell biology2025
Peripheral neuroprotective potential and toxicological profile of fascaplysin in zebrafish models.
Article in Anatomy & cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Regenerative Role of Exosomes as a Potential Therapy for Peripheral Nerve Injury: A Systematic Review.Biomolecules & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fascaplysin is a bioactive compound derived from marine sponges, which have anticancer properties and potential neuroprotective effects mediated by mitigation of oxidative stress-induced neurotoxicity. This study investigated the concentration-dependent effects of fascaplysin in zebrafish models, focusing on embryonic survival, cardiac function, melanocyte formation, and peripheral nerve health. Zebrafish embryos were exposed to fascaplysin at concentrations ranging from 10 nM to 100 μM, and developmental parameters were assessed. At higher concentrations (≥1 μM), fascaplysin significantly decreased embryo survival rates, delayed hatching, impaired cardiac function, and caused morphological abnormalities, including disruption of melanocyte formation and structural deformities. By contrast, lower concentrations (10 nM and 100 nM) did not exhibit significant toxicity. In adult zebrafish, fascaplysin at 100 nM reduced the expression of superoxide-producing enzymes and preserved peripheral nerve integrity following injury, as demonstrated by maintenance of fluorescence in transgenic zebrafish with expression of green fluorescent protein in Schwann cells. These findings suggest that fascaplysin exhibits peripheral neuroprotective effects at low concentrations, potentially through the reduction of oxidative stress and preservation of Schwann cell function. However, the toxicity observed at higher concentrations highlights the importance of dose optimization. Fascaplysin is a promising candidate for the development of new therapeutic strategies for peripheral neuropathies, and further studies are required to elucidate the underlying mechanisms and validate its efficacy in mammalian models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.